The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma

BMC Cancer

Table 4 Summary of systemic studies in epithelioid sarcoma

Author	Institutions	Year	No.	Systemic treatment	ORR (%)	mPFS (month)
Sheri L. Spunt et al.	COG; EpSSG	2005–2015	63	Mainly based on doxorubicin and ifosfamide chemotherapy	50%	5.4 for the metastatic high-risk series
Dario Baratti et al.	Fondazione IRCCS-INT	1986–2005	34	A combination of Adriamycin and ifosfamide	NA	NA
Monika Sparber-Sauer et al.	CWS trials	1981–2016	67	VAIA or CEVAIE;	35%	NA
Monika Sparber-Sauer et al.	CWS trials	1981–2016	67	Gemcitabine and Docetaxel	33%	NA
Scott M. Schuetze et al.	SARC009	2007–2016	7	Dasatinib	28.6%	7.9
Mrinal Gounder et al.	32 hospitals and clinics	2015–2017	62	Tazemetostat	15%	5.5
Current Study	PKUPH	2017–2021	8	Irinotecan, vincristine and TKIs	37.5%	8.0

Abbreviations: No. Patient Number, ORR Objective response rate, mPFS Median progression-free survival, COG Children’s Oncology Group, EpSSG European paediatric soft tissue Sarcoma Study Group, INT Istituto Nazionale Tumori, CWS Cooperative Weichteilsarkom Studiengruppe, SARC009 Sarcoma Alliance Through Research and Collaboration, CBR Clinical benefit rate, NA Data not available, VAIA Vincristine, dactinomycin, ifosfamide and alkylating agent, CEVAIE Carboplatin, etoposide, vincristine, Adriamycin and ifosfamide, PKUPH Peking University People’s Hospital, TKIs Tyrosine kinase inhibitors

ISSN: 1471-2407